Gyre Therapeutics (GYRE) announced Han Ying has stepped down as CEO and will transition into the role of senior VP, science and will oversee research and discovery activities to support Gyre’s fibrosis focused pipeline. Ping Zhang, executive chairman, has been appointed interim CEO, and will lead the company’s day-to-day operations and strategic global expansion.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE: